Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclusivity on semaglutide by 2032, a key drug in its weight-loss portfolio, increasing competition fears. While Novo Nordisk plans to diversify into other health areas, investors are repricing the stock to reflect these challenges. Rival companies like Eli Lilly showed little stock movement, indicating the selloff is specific to Novo Nordisk rather than the sector.
Following Novo Nordisk's announcement of a growth plan that did not exceed industry expectations, its shares dropped sharply by 7.42% on Pluang as of Sep 21, 2026 21:02 WIB, trading at USD 40.03. Meanwhile, Eli Lilly's stock showed resilience with a modest gain of 0.83%, priced at USD 1,161.76. This contrast highlights investor caution specifically around Novo Nordisk's future growth prospects and patent challenges.
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue f...
Anthropic has revealed it operates a wet biology lab where its AI models conduct physical experiments, aiming to bridge AI theories with real-world biology. This lab functions like a typical biotech facility, supporting both in-house research and col...
